BBIO logo

BBIO
BridgeBio Pharma Inc

5,398
Mkt Cap
$14.45B
Volume
12.59M
52W High
$84.94
52W Low
$31.77
PE Ratio
-19.69
BBIO Fundamentals
Price
$69.71
Prev Close
$74.52
Open
$83.20
50D MA
$71.49
Beta
1.30
Avg. Volume
2.08M
EPS (Annual)
-$3.79
P/B
-6.96
Rev/Employee
$598,421.93
$16,800.66
Loading...
Loading...
News
all
press releases
Best Pharmaceutical Stocks To Keep An Eye On - April 28th
Eli Lilly and Company, Pfizer, BridgeBio Pharma, AbbVie, Novo Nordisk A/S, Abbott Laboratories, and Ascendis Pharma A/S are the seven Pharmaceutical stocks to watch today, according to MarketBeat's...
MarketBeat·1h ago
News Placeholder
More News
News Placeholder
BBIO On Track For Worst Day In 2.5 Months: What’s The Pfizer Connection?
BridgeBio is a primary competitor to Pfizer in the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) market.
Stocktwits·3h ago
News Placeholder
BridgeBio Pharma (NASDAQ:BBIO) Shares Gap Up - Here's What Happened
BridgeBio Pharma (NASDAQ:BBIO) Shares Gap Up - What's Next...
MarketBeat·4h ago
News Placeholder
BridgeBio Pharma (NASDAQ:BBIO) Earns "Outperform" Rating from Mizuho
Mizuho restated an "outperform" rating and set a $106.00 price target on shares of BridgeBio Pharma in a report on Tuesday...
MarketBeat·5h ago
News Placeholder
BridgeBio Pharma (BBIO) Expected to Announce Earnings on Tuesday
BridgeBio Pharma (NASDAQ:BBIO) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 5. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-5-bridgebio-pharma-inc-stock...
MarketBeat·5h ago
News Placeholder
Will BridgeBio Pharma (BBIO) Report Negative Q1 Earnings? What You Should Know
BridgeBio Pharma (BBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·7h ago
News Placeholder
HC Wainwright Reiterates Buy Rating for BridgeBio Pharma (NASDAQ:BBIO)
HC Wainwright reissued a "buy" rating and set a $100.00 price objective on shares of BridgeBio Pharma in a research report on Monday...
MarketBeat·1d ago
News Placeholder
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) have been given an average recommendation of "Moderate Buy" by the twenty-five ratings firms that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and twenty-four h...
MarketBeat·3d ago
News Placeholder
M&T Bank Corp Takes Position in BridgeBio Pharma, Inc. $BBIO
M&T Bank Corp purchased a new stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm purchased...
MarketBeat·5d ago
News Placeholder
BridgeBio Pharma (NASDAQ:BBIO) CEO Sells $2,984,800.00 in Stock
BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) CEO Neil Kumar sold 40,000 shares of the business's stock in a transaction that occurred on Thursday, April 9th. The stock was sold at an average price of $74.62, for a total transaction of $2,984,800.00. Following the completion of the...
MarketBeat·15d ago
<
1
2
...
>

Latest BBIO News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.